var data={"title":"Hailey-Hailey disease (benign familial pemphigus)","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Hailey-Hailey disease (benign familial pemphigus)</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/contributors\" class=\"contributor contributor_credentials\">Dean Morrell, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/contributors\" class=\"contributor contributor_credentials\">Jennifer L Hand, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/contributors\" class=\"contributor contributor_credentials\">Rosamaria Corona, MD, DSc</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Feb 13, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H26478746\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Hailey-Hailey disease (HHD, MIM #169600), also called benign familial pemphigus or benign chronic pemphigus, is a rare autosomal dominant disorder that affects the adhesion of epidermal keratinocytes. Initially described by the Hailey brothers in 1939 [<a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/1\" class=\"abstract_t\">1</a>], this intraepidermal blistering disorder is characterized by blistering, erosions, maceration, and frequent secondary infection in the flexural areas. HHD is a chronic condition with multiple recurrences and limited therapeutic options.</p><p>This topic will discuss the pathogenesis, clinical manifestations, diagnosis, and treatment of HHD. Darier disease, a condition that shares many clinical and pathologic features with HHD, is discussed separately. (See <a href=\"topic.htm?path=darier-disease\" class=\"medical medical_review\">&quot;Darier disease&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H26478753\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Hailey-Hailey disease (HHD) is a rare disorder. Its prevalence is unknown, since many patients lack an accurate diagnosis or do not seek treatment. The age of onset and clinical manifestations of HHD can vary widely within families, but presentation during childhood is uncommon [<a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/2\" class=\"abstract_t\">2</a>]. There is no apparent difference in prevalence among different ethnic groups.</p><p class=\"headingAnchor\" id=\"H26478760\"><span class=\"h1\">PATHOGENESIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Hailey-Hailey disease (HHD, MIM #169600) is caused by loss-of-function mutations in the <em>ATP2C1</em> gene at 3q22.1, which encodes the adenosine triphosphate (ATP)-powered, magnesium-dependent calcium pump protein hSPCA1; its function is to maintain normal intracellular concentrations of free calcium (Ca<sup>2+</sup>) by sequestering Ca<sup>2+</sup> into the Golgi apparatus [<a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/3\" class=\"abstract_t\">3</a>].</p><p>HHD is inherited in an autosomal dominant manner with complete penetrance and variable expressivity. Only two-thirds of patients have a family history of HHD; de novo mutations or lack of phenotypic expression in affected family members account for the absence of family history in the remainder. Interfamilial phenotypic variations and the lack of clear genotype-phenotype correlations indicate that environmental <span class=\"nowrap\">and/or</span> other genetic factors may modify the clinical presentation. </p><p>Nearly 180 unique <em>ATP2C1 </em>variants have been reported in families or sporadic patients with HHD [<a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/4,5\" class=\"abstract_t\">4,5</a>]. Missense, nonsense, frameshift, and splice-site mutations have all been reported. <em>ATP2C1 </em>haploinsufficiency is thought to lead to reduced hSPCA1 activity. </p><p>Although the expression of <em>ATP2C1</em> is ubiquitous, HHD is primarily localized to intertriginous areas. Segmental forms showing unilateral or linear distribution represent mosaicism, resulting from postzygotic mutation or loss of heterozygosity at the <em>ATP2C1</em> locus [<a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/6,7\" class=\"abstract_t\">6,7</a>]. Calcium homeostasis in keratinocytes is involved in epidermal differentiation, barrier repair, cell-cell adhesion, and keratinocyte motility. Although the precise mechanism is incompletely understood, the genetic defect results in altered cellular connections within desmosomes and adherens junctions of the epidermis (acantholysis), secondary to high cytosolic calcium levels. </p><p>However, other factors may have a role in the development of the clinical manifestations of HHD, including oxidative stress and microRNAs [<a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/8,9\" class=\"abstract_t\">8,9</a>]. MicroRNAs are small, noncoding RNAs involved in post-transcriptional regulation of gene expression. The microRNA miR-125b, which regulates the expression of factors implicated in keratinocyte proliferation and differentiation, appears to be upregulated in keratinocytes from patients with HHD [<a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/8\" class=\"abstract_t\">8</a>].</p><p class=\"headingAnchor\" id=\"H26478767\"><span class=\"h1\">CLINICAL PRESENTATION AND COURSE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The onset of Hailey-Hailey disease (HHD) typically occurs in the second and third decades of life. The clinical manifestations primarily involve the flexural areas in a symmetric fashion (groin, axillae, lateral neck, submammary region, and perineum). Mucosal involvement is rare. Segmental forms present as unilateral, linear, patchy, or otherwise confined involvement. Linear lesions are often localized along the Blaschko lines (lines for migration of skin and appendages, such as hair, melanocytes, and eccrine glands, during embryogenesis).</p><p>Flaccid vesicles on erythematous to normal skin are the first manifestation and are often not noticed. Large, macerated, exudative plaques of superficial erosions with crusting are usually seen at the time of the diagnosis (<a href=\"image.htm?imageKey=DERM%2F76004%7EDERM%2F61689%7EDERM%2F74552%7EOBGYN%2F80862\" class=\"graphic graphic_picture graphicRef76004 graphicRef61689 graphicRef74552 graphicRef80862 \">picture 1A-D</a>). Further progression to large, vegetative, malodorous plaques with painful fissures can occur. Flexural disease may be disabling, especially if the groin is involved. Longitudinal, white bands of the nails have been described in approximately 70 percent of patients with HHD and can be a clue to the diagnosis [<a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/10\" class=\"abstract_t\">10</a>]. </p><p class=\"headingAnchor\" id=\"H20008536\"><span class=\"h2\">Clinical course</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>HHD has a remitting and relapsing course with a substantial impact on quality of life [<a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/11\" class=\"abstract_t\">11</a>]. When the inflammation remits and lesions heal, postinflammatory hyperpigmentation is a common sequela. Exacerbating factors include sweating, friction, ultraviolet radiation, and cutaneous infections [<a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/10\" class=\"abstract_t\">10</a>].</p><p>Colonization and secondary infection with bacteria (<em>Staphylococcus</em>, <em>Streptococcus</em>) and fungi (dermatophytes, <em>Candida</em>) are common and are a frequent cause of persistence or exacerbation of lesions [<a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/12-14\" class=\"abstract_t\">12-14</a>]. Vegetations and malodor are signs of bacterial or fungal overgrowth. Bacterial and fungal cultures should be performed during relapses to determine appropriate antibiotic or antifungal treatment.</p><p class=\"headingAnchor\" id=\"H23965479\"><span class=\"h2\">Risk of squamous cell carcinoma</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There are anecdotal reports of squamous cell carcinomas arising in vulvar and penile lesions of HHD [<a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/15-17\" class=\"abstract_t\">15-17</a>]. However, it is unclear whether the chronic impairment of the epidermal barrier in HHD increases the risk of infection from oncogenic strains of human papillomavirus [<a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/18\" class=\"abstract_t\">18</a>]. In a mouse model, <em>ATP2C1</em> mutations induced the development of squamous cell tumors in the absence of skin manifestations of HHD [<a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/19\" class=\"abstract_t\">19</a>]. Melanoma and other cancers have also been reported in patients with HHD [<a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/20\" class=\"abstract_t\">20</a>].</p><p class=\"headingAnchor\" id=\"H20009078\"><span class=\"h1\">HISTOPATHOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Histopathologic examination of biopsy samples of lesional skin in Hailey-Hailey disease reveals widespread loss of cohesion among suprabasal keratinocytes (acantholysis), resulting in suprabasal clefts and acantholytic vesicles and bullae. Areas of partial acantholysis form layers of intraepidermal and suprabasal, detached keratinocytes with the appearance of a &quot;dilapidated brick wall&quot; (<a href=\"image.htm?imageKey=DERM%2F75555\" class=\"graphic graphic_picture graphicRef75555 \">picture 2</a>). Dyskeratosis (abnormal keratinization) is usually mild. The papillary dermis contains a sparse, perivascular, lymphocytic infiltrate with scattered eosinophils. Neutrophils may be seen in the vesicles and in the parakeratotic crust [<a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/21\" class=\"abstract_t\">21</a>]. </p><p>In contrast with autoimmune pemphigus, intercellular immunoglobulin G (IgG) is not detected in the epidermis by direct immunofluorescence staining.<sup> </sup>(See <a href=\"topic.htm?path=pathogenesis-clinical-manifestations-and-diagnosis-of-pemphigus#H458196\" class=\"medical medical_review\">&quot;Pathogenesis, clinical manifestations, and diagnosis of pemphigus&quot;, section on 'Diagnosis'</a>.)</p><p class=\"headingAnchor\" id=\"H26478774\"><span class=\"h1\">DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The diagnosis of Hailey-Hailey disease (HHD) is suggested by the clinical finding of characteristic macerated erosions limited to intertriginous areas without satellite lesions and by a history of similar clinical manifestations in other family members. A skin biopsy for histopathologic examination and direct immunofluorescence staining is needed to confirm the diagnosis. (See <a href=\"#H20009078\" class=\"local\">'Histopathology'</a> above.)</p><p>Direct immunofluorescence is negative in HHD and differentiates HHD from pemphigus. (See <a href=\"topic.htm?path=pathogenesis-clinical-manifestations-and-diagnosis-of-pemphigus#H458196\" class=\"medical medical_review\">&quot;Pathogenesis, clinical manifestations, and diagnosis of pemphigus&quot;, section on 'Diagnosis'</a>.)</p><p>Bacterial and fungal cultures of the involved sites are useful to determine appropriate antibiotic or antifungal treatment.</p><p class=\"headingAnchor\" id=\"H2060503153\"><span class=\"h2\">Molecular diagnosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Molecular testing of peripheral blood for DNA mutations in <em>ATP2C1</em> that cause HHD is clinically available, although it is generally not required for the diagnosis. Referral for genetic services can help facilitate counseling, discussion of pros and cons of genetic testing, interpretation of the results, and implications for the family. The American College of Medical Genetics website can be searched by zip code or city and state to find local genetics services [<a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/22\" class=\"abstract_t\">22</a>]. (See <a href=\"#H1785844435\" class=\"local\">'Genetic counseling'</a> below.)</p><p class=\"headingAnchor\" id=\"H26478790\"><span class=\"h1\">DIFFERENTIAL DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Several dermatologic diseases may have clinical features and distribution similar to Hailey-Hailey disease (HHD) [<a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/23\" class=\"abstract_t\">23</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Darier disease</strong> &ndash; Flexural lesions of Darier disease are clinically difficult to differentiate from HHD. However, Darier disease is characterized by greasy, hyperkeratotic papules involving seborrheic areas (such as the scalp, ears, central chest, and upper back) and by a distinctive nail dystrophy (<a href=\"image.htm?imageKey=DERM%2F70000%7EDERM%2F56168%7EDERM%2F81865\" class=\"graphic graphic_picture graphicRef70000 graphicRef56168 graphicRef81865 \">picture 3A-C</a>). Histologically, acantholysis is more widespread in HHD than in Darier disease, whereas dyskeratosis (abnormal, premature keratinization of keratinocytes, which appear as &quot;corps ronds&quot; or &quot;grains&quot;) predominates in Darier disease. (See <a href=\"topic.htm?path=darier-disease\" class=\"medical medical_review\">&quot;Darier disease&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Papular acantholytic dyskeratosis of the vulva </strong>&ndash; Papular acantholytic dyskeratosis (PAD) of the vulva is a rare, chronic disorder presenting in young adult and older women as small, pruritic papules over the vulva and inguinal folds. PAD is a noninherited disorder and is thought to be a mosaic form of Darier disease [<a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/24\" class=\"abstract_t\">24</a>]. However, there are reports of familial cases of PAD, suggesting that PAD may be an allelic variant of HHD [<a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/25,26\" class=\"abstract_t\">25,26</a>]. The histopathologic findings in PAD are characteristically a combination of those seen in both Darier disease and HHD (ie, suprabasal clefting and acantholysis, dyskeratotic cells resembling corps ronds and grains). </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Galli-Galli disease</strong> &ndash; Galli-Galli disease is a rare autosomal dominant disorder characterized by reticulated hyperpigmentation and keratotic, papular lesions involving the major flexural areas. Histologically, there are elongated, finger-like strands of keratinocytes extending into the papillary dermis, hyperpigmentation of the rete ridges, multiple foci of acantholysis, and dyskeratotic cells.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Pemphigus</strong> &ndash; Vegetating, flexural lesions occur in pemphigus vegetans, an uncommon variant of pemphigus vulgaris (<a href=\"image.htm?imageKey=DERM%2F60187\" class=\"graphic graphic_picture graphicRef60187 \">picture 4</a>). A positive direct immunofluorescence confirms the diagnosis of pemphigus. (See <a href=\"topic.htm?path=pathogenesis-clinical-manifestations-and-diagnosis-of-pemphigus#H458196\" class=\"medical medical_review\">&quot;Pathogenesis, clinical manifestations, and diagnosis of pemphigus&quot;, section on 'Diagnosis'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Seborrheic</strong> <strong>dermatitis </strong>&ndash; The involvement of intertriginous areas is possible in seborrheic dermatitis (<a href=\"image.htm?imageKey=DERM%2F53407%7EDERM%2F68137\" class=\"graphic graphic_picture graphicRef53407 graphicRef68137 \">picture 5A-B</a>); however, erythematous plaques <span class=\"nowrap\">and/or</span> yellowish, greasy scales are typically seen on the scalp, eyebrows, or nasolabial folds (<a href=\"image.htm?imageKey=DERM%2F54173%7EDERM%2F76985%7EDERM%2F59104\" class=\"graphic graphic_picture graphicRef54173 graphicRef76985 graphicRef59104 \">picture 6A-C</a>). (See <a href=\"topic.htm?path=seborrheic-dermatitis-in-adolescents-and-adults\" class=\"medical medical_review\">&quot;Seborrheic dermatitis in adolescents and adults&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Inverse</strong> <strong>psoriasis</strong> &ndash; Psoriasis of the intertriginous areas usually lacks scaling and may be difficult to differentiate from other causes of intertrigo (<a href=\"image.htm?imageKey=PC%2F79274%7EDERM%2F78531%7EDERM%2F76200%7EDERM%2F50615%7EOBGYN%2F56110\" class=\"graphic graphic_picture graphicRef79274 graphicRef78531 graphicRef76200 graphicRef50615 graphicRef56110 \">picture 7A-E</a>). However, the presence of psoriatic plaques in nonflexural areas, involvement of the umbilicus, and pitting of nail plates allow for the correct diagnosis (<a href=\"image.htm?imageKey=DERM%2F70962%7EDERM%2F73527\" class=\"graphic graphic_picture graphicRef70962 graphicRef73527 \">picture 8A-B</a>). (See <a href=\"topic.htm?path=epidemiology-clinical-manifestations-and-diagnosis-of-psoriasis#H28373595\" class=\"medical medical_review\">&quot;Epidemiology, clinical manifestations, and diagnosis of psoriasis&quot;, section on 'Inverse psoriasis'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Intertrigo </strong>&ndash; Erythematous, macerated plaques and erosions with peripheral scaling and satellite papulopustules are characteristic of candidal intertrigo (<a href=\"image.htm?imageKey=DERM%2F72073%7EPC%2F78179\" class=\"graphic graphic_picture graphicRef72073 graphicRef78179 \">picture 9A-B</a>). Tinea cruris usually presents with erythematous, scaling plaques with sharp margins, without vesicles or erosions and few satellite lesions (<a href=\"image.htm?imageKey=DERM%2F71067\" class=\"graphic graphic_picture graphicRef71067 \">picture 10</a>). Bacterial colonization, which is common in obese individuals, may cause maceration. (See <a href=\"topic.htm?path=dermatophyte-tinea-infections#H27\" class=\"medical medical_review\">&quot;Dermatophyte (tinea) infections&quot;, section on 'Tinea cruris'</a> and <a href=\"topic.htm?path=candidal-intertrigo#H5\" class=\"medical medical_review\">&quot;Candidal intertrigo&quot;, section on 'Clinical features'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Erythrasma</strong> &ndash; Erythrasma is caused by the overgrowth of <em>Corynebacterium minutissimum</em>, a component of the normal skin flora. It presents with well-defined, <span class=\"nowrap\">erythematous/brown</span> patches in the axillae, inframammary region, or groin (<a href=\"image.htm?imageKey=DERM%2F80242%7EDERM%2F59529%7EDERM%2F51713\" class=\"graphic graphic_picture graphicRef80242 graphicRef59529 graphicRef51713 \">picture 11A-C</a>). A coral-red fluorescence under Wood's lamp examination will confirm the diagnosis (<a href=\"image.htm?imageKey=DERM%2F62143\" class=\"graphic graphic_picture graphicRef62143 \">picture 12</a>). (See <a href=\"topic.htm?path=erythrasma\" class=\"medical medical_review\">&quot;Erythrasma&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Granular parakeratosis </strong>&ndash; Granular parakeratosis is a rare disorder characterized by hyperkeratotic, reddish-brown plaques occurring in intertriginous areas. The diagnosis is based upon the histologic finding of keratohyalin granules within the corneocytes, resulting in a granular appearance of the stratum corneum.</p><p/><p class=\"headingAnchor\" id=\"H1578623156\"><span class=\"h1\">APPROACH TO MANAGEMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There is no specific therapy for Hailey-Hailey disease (HHD). The therapeutic approach to HHD involves the control of exacerbating factors, secondary infections, and cutaneous inflammation. Because of the rarity of the disease, evidence of efficacy for topical or systemic therapies is mainly based upon small observational studies, case reports, and clinical experience.</p><p class=\"headingAnchor\" id=\"H3023347860\"><span class=\"h2\">General measures</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Since heat, moisture, and friction provoke cutaneous flares of HHD, all patients with HHD will benefit from measures aimed at reducing sweating, friction, and bacterial colonization in the involved areas:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Reduction of body weight if appropriate</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Use of light-weight, loose clothing</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Avoidance of very hot environments</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Use of absorbent pads in skin folds to reduce moisture</p><p/><p>Open, crusted, macerated, and malodorous lesions can be treated with diluted bleach (0.5 cup or 120 mL of 6% bleach in a full bathtub of water [40 gallons or 150 L] or 1 tsp or 5 mL of bleach in one gallon of water [3.8 L]). This may be applied as baths, soaks, or compresses on a regular basis (eg, two to three times per week) to decrease staphylococcal carriage. Alternatively, antibacterial washes, such as <a href=\"topic.htm?path=chlorhexidine-gluconate-drug-information\" class=\"drug drug_general\">chlorhexidine</a> gluconate 4% wash, may be used on a daily basis. Topical compresses of <a href=\"topic.htm?path=aluminum-acetate-drug-information\" class=\"drug drug_general\">aluminum acetate</a> solution at a 1:40 dilution, applied intermittently for 5 to 10 minutes, may also be beneficial for macerated lesions.</p><p class=\"headingAnchor\" id=\"H3072059043\"><span class=\"h2\">First-line therapies</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For patients with mild disease, topical antibiotics and intermittent use of topical corticosteroids or topical calcineurin inhibitors are the first-line treatment. Antibacterial washes such as <a href=\"topic.htm?path=chlorhexidine-gluconate-drug-information\" class=\"drug drug_general\">chlorhexidine</a> gluconate 4% wash may be used as an adjunct to topical antibiotics. (See <a href=\"#H9327898\" class=\"local\">'Topical and intralesional therapies'</a> below.)</p><p>We suggest <a href=\"topic.htm?path=clindamycin-drug-information\" class=\"drug drug_general\">clindamycin</a> 1% lotion or cream, <a href=\"topic.htm?path=gentamicin-drug-information\" class=\"drug drug_general\">gentamicin</a> 0.1% cream, or <a href=\"topic.htm?path=mupirocin-drug-information\" class=\"drug drug_general\">mupirocin</a> 2% cream. Antibiotic lotions or creams are applied to the affected areas two to four times per day for two to four weeks. In children, ointment preparations are generally better tolerated than lotions or creams. </p><p><a href=\"topic.htm?path=ketoconazole-drug-information\" class=\"drug drug_general\">Ketoconazole</a> 2% cream or other azole cream may be helpful for patients with fungal colonization. Antifungal creams are applied twice daily for two to four weeks. </p><p>Short courses of moderate- to high-potency topical corticosteroids (groups 3 and 4 (<a href=\"image.htm?imageKey=DERM%2F62402\" class=\"graphic graphic_table graphicRef62402 \">table 1</a>)) may be used in conjunction with topical antimicrobials to treat episodes of exacerbation. Topical corticosteroids are applied twice a day for five to seven days. <a href=\"topic.htm?path=tacrolimus-drug-information\" class=\"drug drug_general\">Tacrolimus</a> ointment may be an alternative to topical corticosteroids for long-term control of inflammation. Tacrolimus 0.1% ointment is applied twice a day until resolution of the lesions.</p><p>For patients with frequent exacerbations due to heavy microbial colonization, systemic treatment with oral antibiotics or antifungals, guided by the culture's results, may be required. (See <a href=\"#H9327940\" class=\"local\">'Systemic therapies'</a> below.) </p><p class=\"headingAnchor\" id=\"H2203744409\"><span class=\"h2\">Second-line therapies</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For patients with extensive or severe disease, intermittent injections of botulinum toxin aimed at reducing sweating and maceration may be an adjunct to topical antimicrobial and anti-inflammatory therapies. Botulinum toxin type A is injected into the axillae or inguinal folds with the same technique used in the treatment of hyperhidrosis [<a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/27\" class=\"abstract_t\">27</a>]. (See <a href=\"topic.htm?path=primary-focal-hyperhidrosis#H706301202\" class=\"medical medical_review\">&quot;Primary focal hyperhidrosis&quot;, section on 'Botulinum toxin'</a>.)</p><p>For the rare cases of severe and recalcitrant disease, <a href=\"topic.htm?path=cyclosporine-ciclosporin-drug-information\" class=\"drug drug_general\">cyclosporine</a> 2.5 to 3.5 <span class=\"nowrap\">mg/kg</span> per day, <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a> 15 <span class=\"nowrap\">mg/week,</span> or <a href=\"topic.htm?path=acitretin-drug-information\" class=\"drug drug_general\">acitretin</a> 25 <span class=\"nowrap\">mg/day</span> are options to be tried prior to destructive approaches with laser <span class=\"nowrap\">and/or</span> surgery [<a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/28-31\" class=\"abstract_t\">28-31</a>]. (See <a href=\"#H9327940\" class=\"local\">'Systemic therapies'</a> below and <a href=\"#H2625410684\" class=\"local\">'Surgical or destructive therapies'</a> below.)</p><p class=\"headingAnchor\" id=\"H3577992220\"><span class=\"h1\">THERAPEUTIC OPTIONS</span></p><p class=\"headingAnchor\" id=\"H9327898\"><span class=\"h2\">Topical and intralesional therapies</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Topical therapies for Hailey-Hailey disease (HHD) are aimed at controlling the overgrowth of microbial flora and reducing inflammation. Efficacy has not been evaluated in clinical trials, and their use is mainly based on small observational studies and case reports and clinical experience. Topical treatments include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Topical antimicrobials</strong> &ndash; Long-term use of topical antibiotics (eg, <a href=\"topic.htm?path=clindamycin-drug-information\" class=\"drug drug_general\">clindamycin</a> 1% lotion or cream, <a href=\"topic.htm?path=gentamicin-drug-information\" class=\"drug drug_general\">gentamicin</a> 0.1% cream, or <a href=\"topic.htm?path=mupirocin-drug-information\" class=\"drug drug_general\">mupirocin</a> 2% cream) <span class=\"nowrap\">and/or</span> antifungals (eg, <a href=\"topic.htm?path=ketoconazole-drug-information\" class=\"drug drug_general\">ketoconazole</a> 2% cream or other azole cream) appears to be beneficial in small case series and reports [<a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/10,32\" class=\"abstract_t\">10,32</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Topical corticosteroids</strong> &ndash; Moderate- to high-potency corticosteroids (groups 3 and 4 (<a href=\"image.htm?imageKey=DERM%2F62402\" class=\"graphic graphic_table graphicRef62402 \">table 1</a>)) may be used intermittently as an adjunct to topical antibiotics and antifungals [<a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/33\" class=\"abstract_t\">33</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Topical calcineurin inhibitors</strong> &ndash; <a href=\"topic.htm?path=tacrolimus-drug-information\" class=\"drug drug_general\">Tacrolimus</a> 0.1% ointment, alone or in combination with other treatments, has been reported as beneficial in several case reports [<a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/34-37\" class=\"abstract_t\">34-37</a>]. Clinical improvement generally occurs after two weeks of treatment.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Botulinum toxin type A</strong> &ndash; Botulinum toxin injection in areas of HHD has been used in a small number of cases as an adjunctive treatment to reduce sweating and maceration [<a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/27,38-41\" class=\"abstract_t\">27,38-41</a>]. In a series of six cases, botulin toxin type A, 500 units, was injected into the axillae or inguinal folds, following the technique used in the treatment of hyperhidrosis [<a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/27\" class=\"abstract_t\">27</a>]. There were no flares four months after treatment in one patient and no flares at two months in two additional cases. (See <a href=\"topic.htm?path=primary-focal-hyperhidrosis#H706301202\" class=\"medical medical_review\">&quot;Primary focal hyperhidrosis&quot;, section on 'Botulinum toxin'</a>.)</p><p/><p>There are isolated reports of successful treatment with topical <a href=\"topic.htm?path=calcitriol-drug-information\" class=\"drug drug_general\">calcitriol</a> [<a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/42\" class=\"abstract_t\">42</a>]<sup> </sup>and 5-fluorouracil [<a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/43\" class=\"abstract_t\">43</a>]. However, treatment follow-up was limited to three months, with only one or two cases reported. </p><p class=\"headingAnchor\" id=\"H9327940\"><span class=\"h2\">Systemic therapies</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Intermittent courses of oral antibiotics are occasionally used to control episodes of increased disease activity. The choice of antibiotic is determined by the patient's culture results. Some advocate use of tetracyclines because of their additional anti-inflammatory effect.</p><p>Other systemic therapies anecdotally reported as beneficial include cyclosporin 2.5 to 3.5 <span class=\"nowrap\">mg/kg</span> per day [<a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/28,29,44\" class=\"abstract_t\">28,29,44</a>], <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a> 15 <span class=\"nowrap\">mg/week</span> [<a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/30,31\" class=\"abstract_t\">30,31</a>], <a href=\"topic.htm?path=acitretin-drug-information\" class=\"drug drug_general\">acitretin</a> 25 <span class=\"nowrap\">mg/day</span> [<a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/45,46\" class=\"abstract_t\">45,46</a>], <a href=\"topic.htm?path=glycopyrrolate-glycopyrronium-drug-information\" class=\"drug drug_general\">glycopyrrolate</a> 1 <span class=\"nowrap\">mg/day</span> [<a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/47\" class=\"abstract_t\">47</a>], oral <a href=\"topic.htm?path=tacrolimus-drug-information\" class=\"drug drug_general\">tacrolimus</a> [<a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/48\" class=\"abstract_t\">48</a>], and afamelanotide 16 mg in a sustained-release, resorbable implant formulation [<a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/49\" class=\"abstract_t\">49</a>]. </p><p class=\"headingAnchor\" id=\"H2625410684\"><span class=\"h2\">Surgical or destructive therapies</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Surgical and destructive methods have been used in a few patients with recalcitrant HHD and include [<a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/50\" class=\"abstract_t\">50</a>]: </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Surgical excision [<a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/51,52\" class=\"abstract_t\">51,52</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Carbon dioxide laser or 595 nm pulsed dye laser ablation [<a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/53-57\" class=\"abstract_t\">53-57</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Argon plasma coagulation [<a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/58\" class=\"abstract_t\">58</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Cold atmospheric plasma [<a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/59\" class=\"abstract_t\">59</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Dermabrasion [<a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/60-62\" class=\"abstract_t\">60-62</a>] </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Photodynamic therapy [<a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/63-66\" class=\"abstract_t\">63-66</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Electron beam radiation [<a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/67\" class=\"abstract_t\">67</a>]</p><p/><p>Drawbacks of surgical and destructive therapies include long healing time, pain, scarring, and uncertain long-term benefit. </p><p class=\"headingAnchor\" id=\"H2967527976\"><span class=\"h2\">Emerging medical therapies</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Serendipitous, patient-reported observations have drawn attention to two promising therapies for HHD: oral <a href=\"topic.htm?path=magnesium-chloride-drug-information\" class=\"drug drug_general\">magnesium chloride</a> supplementation and low-dose oral <a href=\"topic.htm?path=naltrexone-drug-information\" class=\"drug drug_general\">naltrexone</a>.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=magnesium-chloride-drug-information\" class=\"drug drug_general\">Magnesium chloride</a> &ndash; In three patients, magnesium chloride, taken once daily as an oral solution containing approximately 300 mg of elemental magnesium, induced a rapid improvement in HHD lesions, with nearly complete resolution in four weeks [<a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/68,69\" class=\"abstract_t\">68,69</a>]. No adverse effects were reported. In one patient, the electrolyte serum levels, including calcemia and magnesemia, were normal after 12 months of continued treatment [<a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/69\" class=\"abstract_t\">69</a>]. </p><p/><p class=\"bulletIndent1\">Although the mechanism of action of <a href=\"topic.htm?path=magnesium-chloride-drug-information\" class=\"drug drug_general\">magnesium chloride</a> supplementation in HHD has not been clarified, one hypothesis is that it may affect the altered intracellular calcium homeostasis in HHD keratinocytes. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=naltrexone-drug-information\" class=\"drug drug_general\">Naltrexone</a> &ndash; Naltrexone, an opioid antagonist used in the treatment of alcohol and opioid dependence, has been found to be effective for the treatment of HHD [<a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/70,71\" class=\"abstract_t\">70,71</a>]. The mechanism of action of naltrexone in HHD is unclear. One hypothesis is that its effect may be due to its anti-inflammatory properties, as well as to some influence on intracellular calcium homeostasis. </p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>In one report, three patients with recalcitrant HHD were treated with low-dose <a href=\"topic.htm?path=naltrexone-drug-information\" class=\"drug drug_general\">naltrexone</a> hydrochloride given orally at a dose of 1.5 to 3 mg per day, after stopping all other topical or systemic therapies [<a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/71\" class=\"abstract_t\">71</a>]. All three patients achieved an 80 to 90 percent clinical improvement, defined as resolution of erosions, improvement in erythema, and decrease in tenderness and discomfort, after three to four months of treatment with naltrexone. </p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>In another report, three patients older than 50 years with long-standing HHD were treated with oral <a href=\"topic.htm?path=naltrexone-drug-information\" class=\"drug drug_general\">naltrexone</a> 3 mg and up to 4.5 mg per day [<a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/70\" class=\"abstract_t\">70</a>]. Erosions began to heal from the peripheral within one to two weeks of starting treatment and were completely resolved at four months. No major adverse effects were reported with low-dose naltrexone. Minor adverse effects included headache, gastrointestinal symptoms, and vivid dreams. In both reports, discontinuing low-dose naltrexone resulted in a relapse of HHD within a few days, which resolved within a week of restarting therapy. </p><p/><p>Although promising, the results of these reports need to be confirmed in additional studies before <a href=\"topic.htm?path=magnesium-chloride-drug-information\" class=\"drug drug_general\">magnesium chloride</a> and low-dose <a href=\"topic.htm?path=naltrexone-drug-information\" class=\"drug drug_general\">naltrexone</a> can be recommended for the treatment of severe recalcitrant HHD. </p><p class=\"headingAnchor\" id=\"H1785844435\"><span class=\"h1\">GENETIC COUNSELING</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For patients with Hailey-Hailey disease (HHD), offering referral for genetics services to discuss inheritance pattern, recurrence risk, pros and cons of genetic testing, and reproductive options (such as preimplantation genetic diagnosis) is appropriate. (See <a href=\"#H2060503153\" class=\"local\">'Molecular diagnosis'</a> above.)</p><p>Because HHD is an autosomal dominant disorder, an affected person will have up to a one in two chance of having a child who is also affected. Prenatal diagnosis is possible for future children in a family when the causative mutation in a parent is known.</p><p class=\"headingAnchor\" id=\"H9328049\"><span class=\"h1\">PROGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Hailey-Hailey disease (HHD) has a chronic, relapsing, and remitting course. The long-term benefits of medical <span class=\"nowrap\">and/or</span> surgical approaches to HHD are uncertain, and recurrence is common. Patients with HHD have a normal life expectancy, although with significantly impaired quality of life. </p><p class=\"headingAnchor\" id=\"H26478811\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hailey-Hailey disease (HHD), also called &quot;benign familial pemphigus,&quot; is an autosomal dominant genodermatosis characterized by blistering, erosions, maceration, and frequent secondary infection in the flexural areas due to loss of keratinocyte adhesion (acantholysis). HHD is caused by mutations in the <em>ATP2C1</em> gene, encoding an adenosine triphosphate (ATP)-powered calcium pump. (See <a href=\"#H26478746\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Intertriginous areas are primarily affected with malodorous, macerated plaques of superficial vesicles and erosions (<a href=\"image.htm?imageKey=DERM%2F76004%7EDERM%2F61689%7EDERM%2F74552%7EOBGYN%2F80862\" class=\"graphic graphic_picture graphicRef76004 graphicRef61689 graphicRef74552 graphicRef80862 \">picture 1A-D</a>). Secondary cutaneous infections are common and trigger disease exacerbations. (See <a href=\"#H26478767\" class=\"local\">'Clinical presentation and course'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The diagnosis of HHD is suggested by the clinical findings. A skin biopsy for histopathologic examination and direct immunofluorescence staining is needed to confirm the diagnosis and rule out other dermatoses with similar clinical findings and lesion distribution. Molecular testing of peripheral blood cells for causative DNA mutations in the <em>ATP2C1</em> gene is clinically available. (See <a href=\"#H26478774\" class=\"local\">'Diagnosis'</a> above and <a href=\"#H2060503153\" class=\"local\">'Molecular diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>There is no specific therapy for HHD. Its management involves the control of exacerbating factors, secondary infections, and cutaneous inflammation. (See <a href=\"#H1578623156\" class=\"local\">'Approach to management'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with mild disease, we suggest initial treatment with topical antibiotics such as <a href=\"topic.htm?path=clindamycin-drug-information\" class=\"drug drug_general\">clindamycin</a> 1% lotion or cream, <a href=\"topic.htm?path=gentamicin-drug-information\" class=\"drug drug_general\">gentamicin</a> 0.1% cream, or <a href=\"topic.htm?path=mupirocin-drug-information\" class=\"drug drug_general\">mupirocin</a> 2% cream for two to four weeks (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). Short courses (five to seven days) of moderate- to high-potency topical corticosteroids (groups 3 and 4 (<a href=\"image.htm?imageKey=DERM%2F62402\" class=\"graphic graphic_table graphicRef62402 \">table 1</a>)) may be used in conjunction with topical antimicrobials to treat episodes of exacerbations. (See <a href=\"#H3072059043\" class=\"local\">'First-line therapies'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with extensive or severe disease, intermittent injections of botulinum toxin aimed at reducing sweating and maceration may be an adjunct to antimicrobial and anti-inflammatory therapies. For the rare cases of severe and recalcitrant disease, oral <a href=\"topic.htm?path=cyclosporine-ciclosporin-drug-information\" class=\"drug drug_general\">cyclosporine</a>, <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a>, or <a href=\"topic.htm?path=acitretin-drug-information\" class=\"drug drug_general\">acitretin</a> are options to be tried prior to destructive approaches with laser <span class=\"nowrap\">and/or</span> surgery. (See <a href=\"#H2203744409\" class=\"local\">'Second-line therapies'</a> above and <a href=\"#H2625410684\" class=\"local\">'Surgical or destructive therapies'</a> above.) </p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/1\" class=\"nounderline abstract_t\">Hailey H, Hailey H. Familial benign chronic pemphigus. Arch Dermatol 1939; 39:679.</a></li><li><a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/2\" class=\"nounderline abstract_t\">Xu Z, Zhang L, Xiao Y, et al. A case of Hailey-Hailey disease in an infant with a new ATP2C1 gene mutation. Pediatr Dermatol 2011; 28:165.</a></li><li><a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/3\" class=\"nounderline abstract_t\">Hu Z, Bonifas JM, Beech J, et al. Mutations in ATP2C1, encoding a calcium pump, cause Hailey-Hailey disease. Nat Genet 2000; 24:61.</a></li><li><a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/4\" class=\"nounderline abstract_t\">Nellen RG, Steijlen PM, van Steensel MA, et al. Mendelian Disorders of Cornification Caused by Defects in Intracellular Calcium Pumps: Mutation Update and Database for Variants in ATP2A2 and ATP2C1 Associated with Darier Disease and Hailey-Hailey Disease. Hum Mutat 2017; 38:343.</a></li><li class=\"breakAll\">www.lovd.nl/ATP2C1 (Accessed on August 16, 2017).</li><li><a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/6\" class=\"nounderline abstract_t\">Poblete-Guti&eacute;rrez P, Wiederholt T, K&ouml;nig A, et al. Allelic loss underlies type 2 segmental Hailey-Hailey disease, providing molecular confirmation of a novel genetic concept. J Clin Invest 2004; 114:1467.</a></li><li><a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/7\" class=\"nounderline abstract_t\">Hwang LY, Lee JB, Richard G, et al. Type 1 segmental manifestation of Hailey-Hailey disease. J Am Acad Dermatol 2003; 49:712.</a></li><li><a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/8\" class=\"nounderline abstract_t\">Manca S, Magrelli A, Cialfi S, et al. Oxidative stress activation of miR-125b is part of the molecular switch for Hailey-Hailey disease manifestation. Exp Dermatol 2011; 20:932.</a></li><li><a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/9\" class=\"nounderline abstract_t\">Cialfi S, Oliviero C, Ceccarelli S, et al. Complex multipathways alterations and oxidative stress are associated with Hailey-Hailey disease. Br J Dermatol 2010; 162:518.</a></li><li><a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/10\" class=\"nounderline abstract_t\">Burge SM. Hailey-Hailey disease: the clinical features, response to treatment and prognosis. Br J Dermatol 1992; 126:275.</a></li><li><a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/11\" class=\"nounderline abstract_t\">Gisondi P, Sampogna F, Annessi G, et al. Severe impairment of quality of life in Hailey-Hailey disease. Acta Derm Venereol 2005; 85:132.</a></li><li><a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/12\" class=\"nounderline abstract_t\">Flint ID, Spencer DM, Wilkin JK. Eczema herpeticum in association with familial benign chronic pemphigus. J Am Acad Dermatol 1993; 28:257.</a></li><li><a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/13\" class=\"nounderline abstract_t\">Chen MY, Chiu HC, Su LH, et al. Presence of human papillomavirus type 6 DNA in the perineal verrucoid lesions of Hailey-Hailey disease. J Eur Acad Dermatol Venereol 2006; 20:1356.</a></li><li><a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/14\" class=\"nounderline abstract_t\">Chan CC, Thong HY, Chan YC, Liao YH. Human papillomavirus type 5 infection in a patient with Hailey-Hailey disease successfully treated with imiquimod. Br J Dermatol 2007; 156:579.</a></li><li><a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/15\" class=\"nounderline abstract_t\">Holst VA, Fair KP, Wilson BB, Patterson JW. Squamous cell carcinoma arising in Hailey-Hailey disease. J Am Acad Dermatol 2000; 43:368.</a></li><li><a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/16\" class=\"nounderline abstract_t\">Cockayne SE, Rassl DM, Thomas SE. Squamous cell carcinoma arising in Hailey-Hailey disease of the vulva. Br J Dermatol 2000; 142:540.</a></li><li><a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/17\" class=\"nounderline abstract_t\">Chun SI, Whang KC, Su WP. Squamous cell carcinoma arising in Hailey-Hailey disease. J Cutan Pathol 1988; 15:234.</a></li><li><a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/18\" class=\"nounderline abstract_t\">Ochiai T, Honda A, Morishima T, et al. Human papillomavirus types 16 and 39 in a vulval carcinoma occurring in a woman with Hailey-Hailey disease. Br J Dermatol 1999; 140:509.</a></li><li><a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/19\" class=\"nounderline abstract_t\">Okunade GW, Miller ML, Azhar M, et al. Loss of the Atp2c1 secretory pathway Ca(2+)-ATPase (SPCA1) in mice causes Golgi stress, apoptosis, and midgestational death in homozygous embryos and squamous cell tumors in adult heterozygotes. J Biol Chem 2007; 282:26517.</a></li><li><a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/20\" class=\"nounderline abstract_t\">Mohr MR, Erdag G, Shada AL, et al. Two patients with Hailey-Hailey disease, multiple primary melanomas, and other cancers. Arch Dermatol 2011; 147:211.</a></li><li class=\"breakAll\">Weedon D. Disorders of epidermal maturation and keratinization. In: Weedon's Skin Pathology, 3rd ed, David Weedon (Ed), Elsevier Health, 2010.</li><li class=\"breakAll\">www.acmg.net/ACMG/Find_Genetic_Services/ACMG/ISGweb/FindaGeneticService.aspx?hkey=720856ab-a827-42fb-a788-b618b15079f9 (Accessed on September 11, 2017).</li><li><a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/23\" class=\"nounderline abstract_t\">Wolf R, Oumeish OY, Parish LC. Intertriginous eruption. Clin Dermatol 2011; 29:173.</a></li><li><a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/24\" class=\"nounderline abstract_t\">Knopp EA, Saraceni C, Moss J, et al. Somatic ATP2A2 mutation in a case of papular acantholytic dyskeratosis: mosaic Darier disease. J Cutan Pathol 2015; 42:853.</a></li><li><a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/25\" class=\"nounderline abstract_t\">Pernet C, Bessis D, Savignac M, et al. Genitoperineal papular acantholytic dyskeratosis is allelic to Hailey-Hailey disease. Br J Dermatol 2012; 167:210.</a></li><li><a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/26\" class=\"nounderline abstract_t\">Yu WY, Ng E, Hale C, et al. Papular acantholytic dyskeratosis of the vulva associated with familial Hailey-Hailey disease. Clin Exp Dermatol 2016; 41:628.</a></li><li><a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/27\" class=\"nounderline abstract_t\">Koeyers WJ, Van Der Geer S, Krekels G. Botulinum toxin type A as an adjuvant treatment modality for extensive Hailey-Hailey disease. J Dermatolog Treat 2008; 19:251.</a></li><li><a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/28\" class=\"nounderline abstract_t\">Berth-Jones J, Smith SG, Graham-Brown RA. Benign familial chronic pemphigus (Hailey-Hailey disease) responds to cyclosporin. Clin Exp Dermatol 1995; 20:70.</a></li><li><a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/29\" class=\"nounderline abstract_t\">Nanda A, Khawaja F, Harbi R, et al. Benign familial pemphigus (Hailey-Hailey disease) responsive to low dose cyclosporine. Indian J Dermatol Venereol Leprol 2010; 76:422.</a></li><li><a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/30\" class=\"nounderline abstract_t\">Fairris GM, White JE, Leppard BJ, Goodwin PG. Methotrexate for intractable benign familial chronic pemphigus. Br J Dermatol 1986; 115:640.</a></li><li><a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/31\" class=\"nounderline abstract_t\">Vilarinho C, Ventura F, Brito C. Methotrexate for refractory Hailey-Hailey disease. J Eur Acad Dermatol Venereol 2010; 24:106.</a></li><li><a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/32\" class=\"nounderline abstract_t\">Galimberti RL, Kowalczuk AM, Bianchi O, et al. Chronic benign familial pemphigus. Int J Dermatol 1988; 27:495.</a></li><li><a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/33\" class=\"nounderline abstract_t\">Ikeda S, Suga Y, Ogawa H. Successful management of Hailey-Hailey disease with potent topical steroid ointment. J Dermatol Sci 1993; 5:205.</a></li><li><a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/34\" class=\"nounderline abstract_t\">Rocha Paris F, Fidalgo A, Baptista J, et al. Topical tacrolimus in Hailey-Hailey disease. Int J Tissue React 2005; 27:151.</a></li><li><a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/35\" class=\"nounderline abstract_t\">Umar SA, Bhattacharjee P, Brodell RT. Treatment of Hailey-Hailey disease with tacrolimus ointment and clobetasol propionate foam. J Drugs Dermatol 2004; 3:200.</a></li><li><a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/36\" class=\"nounderline abstract_t\">Persi&#263;-Vojinovi&#263; S, Milavec-Pureti&#263; V, Dobri&#263; I, et al. Disseminated Hailey-Hailey disease treated with topical tacrolimus and oral erythromycin: Case report and review of the literature. Acta Dermatovenerol Croat 2006; 14:253.</a></li><li><a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/37\" class=\"nounderline abstract_t\">Rabeni EJ, Cunningham NM. Effective treatment of Hailey-Hailey disease with topical tacrolimus. J Am Acad Dermatol 2002; 47:797.</a></li><li><a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/38\" class=\"nounderline abstract_t\">Lapiere JC, Hirsh A, Gordon KB, et al. Botulinum toxin type A for the treatment of axillary Hailey-Hailey disease. Dermatol Surg 2000; 26:371.</a></li><li><a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/39\" class=\"nounderline abstract_t\">Bessa GR, Grazziotin TC, Manzoni AP, et al. Hailey-Hailey disease treatment with Botulinum toxin type A. An Bras Dermatol 2010; 85:717.</a></li><li><a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/40\" class=\"nounderline abstract_t\">Bagherani N, Smoller BR. The efficacy of botulinum toxin type A in the treatment of Hailey-Hailey disease. Dermatol Ther 2016; 29:394.</a></li><li><a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/41\" class=\"nounderline abstract_t\">Dousset L, Pham-Ledard A, Doutre MS, et al. [Treatment of Hailey-Hailey disease with botulinic toxin: A retrospective study of 8 cases]. Ann Dermatol Venereol 2017; 144:599.</a></li><li><a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/42\" class=\"nounderline abstract_t\">Bianchi L, Chimenti MS, Giunta A. Treatment of Hailey-Hailey disease with topical calcitriol. J Am Acad Dermatol 2004; 51:475.</a></li><li><a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/43\" class=\"nounderline abstract_t\">Dammak A, Camus M, Anyfantakis V, Guillet G. Successful treatment of Hailey-Hailey disease with topical 5-fluorouracil. Br J Dermatol 2009; 161:967.</a></li><li><a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/44\" class=\"nounderline abstract_t\">Varada S, Ramirez-Fort MK, Argobi Y, Simkin AD. Remission of refractory benign familial chronic pemphigus (hailey-hailey disease) with the addition of systemic cyclosporine. J Cutan Med Surg 2015; 19:163.</a></li><li><a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/45\" class=\"nounderline abstract_t\">Hunt MJ, Salisbury EL, Painter DM, Lee S. Vesiculobullous Hailey-Hailey disease: successful treatment with oral retinoids. Australas J Dermatol 1996; 37:196.</a></li><li><a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/46\" class=\"nounderline abstract_t\">Berger EM, Galadari HI, Gottlieb AB. Successful treatment of Hailey-Hailey disease with acitretin. J Drugs Dermatol 2007; 6:734.</a></li><li><a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/47\" class=\"nounderline abstract_t\">Kaniszewska M, Rovner R, Arshanapalli A, Tung R. Oral glycopyrrolate for the treatment of Hailey-Hailey disease. JAMA Dermatol 2015; 151:328.</a></li><li><a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/48\" class=\"nounderline abstract_t\">Bedi M, Taylor AL. Recalcitrant Hailey-Hailey disease responds to oral tacrolimus and botulinum toxin type A. Cutis 2015; 96:E14.</a></li><li><a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/49\" class=\"nounderline abstract_t\">Biolcati G, Aurizi C, Barbieri L, et al. Efficacy of the melanocortin analogue Nle4-D-Phe7-&alpha;-melanocyte-stimulating hormone in the treatment of patients with Hailey-Hailey disease. Clin Exp Dermatol 2014; 39:168.</a></li><li><a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/50\" class=\"nounderline abstract_t\">Farahnik B, Blattner CM, Mortazie MB, et al. Interventional treatments for Hailey-Hailey disease. J Am Acad Dermatol 2017; 76:551.</a></li><li><a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/51\" class=\"nounderline abstract_t\">Menz P, Jackson IT, Connolly S. Surgical control of Hailey-Hailey disease. Br J Plast Surg 1987; 40:557.</a></li><li><a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/52\" class=\"nounderline abstract_t\">Aubert JP, Folchetti G, Berbis P, Magalon G. [Surgical treatment of Hailey-Hailey disease or benign chronic familial pemphigus. Apropos of a case of submammary localization]. Ann Chir Plast Esthet 1993; 38:568.</a></li><li><a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/53\" class=\"nounderline abstract_t\">Don PC, Carney PS, Lynch WS, et al. Carbon dioxide laserabrasion: a new approach to management of familial benign chronic pemphigus (Hailey-Hailey disease). J Dermatol Surg Oncol 1987; 13:1187.</a></li><li><a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/54\" class=\"nounderline abstract_t\">Kukova G, Homey B, Bruch-Gerharz D, Diedrichson E. [Familial benign chronic pemphigus (Hailey-Hailey disease): successful treatment with carbon dioxide laser]. Hautarzt 2011; 62:258.</a></li><li><a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/55\" class=\"nounderline abstract_t\">McElroy JA, Mehregan DA, Roenigk RK. Carbon dioxide laser vaporization of recalcitrant symptomatic plaques of Hailey-Hailey disease and Darier's disease. J Am Acad Dermatol 1990; 23:893.</a></li><li><a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/56\" class=\"nounderline abstract_t\">Hunt KM, Jensen JD, Walsh SB, et al. Successful treatment of refractory Hailey-Hailey disease with a 595-nm pulsed dye laser: a series of 7 cases. J Am Acad Dermatol 2015; 72:735.</a></li><li><a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/57\" class=\"nounderline abstract_t\">Falto-Aizpurua LA, Griffith RD, Yazdani Abyaneh MA, Nouri K. Laser therapy for the treatment of Hailey-Hailey disease: a systematic review with focus on carbon dioxide laser resurfacing. J Eur Acad Dermatol Venereol 2015; 29:1045.</a></li><li><a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/58\" class=\"nounderline abstract_t\">Stolze I, Hamm H, Weyandt GH. Segmental multilayered argon plasma coagulation: effective therapy option for perianal and scrotal Hailey-Hailey disease. Colorectal Dis 2011; 13:802.</a></li><li><a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/59\" class=\"nounderline abstract_t\">Isbary G, Morfill G, Zimmermann J, et al. Cold atmospheric plasma: a successful treatment of lesions in Hailey-Hailey disease. Arch Dermatol 2011; 147:388.</a></li><li><a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/60\" class=\"nounderline abstract_t\">LeBlanc KG Jr, Wharton JB, Sheehan DJ. Refractory Hailey-Hailey disease successfully treated with sandpaper dermabrasion. Skinmed 2011; 9:263.</a></li><li><a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/61\" class=\"nounderline abstract_t\">Hamm H, Metze D, Br&ouml;cker EB. Hailey-Hailey disease. Eradication by dermabrasion. Arch Dermatol 1994; 130:1143.</a></li><li><a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/62\" class=\"nounderline abstract_t\">Kirtschig G, Gieler U, Happle R. Treatment of Hailey-Hailey disease by dermabrasion. J Am Acad Dermatol 1993; 28:784.</a></li><li><a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/63\" class=\"nounderline abstract_t\">Ruiz-Rodriguez R, Alvarez JG, Ja&eacute;n P, et al. Photodynamic therapy with 5-aminolevulinic acid for recalcitrant familial benign pemphigus (Hailey-Hailey disease). J Am Acad Dermatol 2002; 47:740.</a></li><li><a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/64\" class=\"nounderline abstract_t\">Fern&aacute;ndez Guarino M, Ryan AM, Harto A, et al. Experience with photodynamic therapy in Hailey-Hailey disease. J Dermatolog Treat 2008; 19:288.</a></li><li><a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/65\" class=\"nounderline abstract_t\">Lobato-Berezo A, Imbern&oacute;n-Moya A, Aguilar-Mart&iacute;nez A. Refractory Hailey-Hailey Disease That Responded Well to Photodynamic Therapy. Actas Dermosifiliogr 2015; 106:852.</a></li><li><a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/66\" class=\"nounderline abstract_t\">Alsahli M, Debu A, Girard C, et al. Is photodynamic therapy a relevant therapeutic option in refractory benign familial pemphigus (Hailey-Hailey disease)? A series of eight patients. J Dermatolog Treat 2017; 28:678.</a></li><li><a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/67\" class=\"nounderline abstract_t\">Graham PM, Melkonian A, Fivenson D. Familial benign chronic pemphigus (Hailey-Hailey disease) treated with electron beam radiation. JAAD Case Rep 2016; 2:159.</a></li><li><a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/68\" class=\"nounderline abstract_t\">Barde NG, Mishra DB, Ingole SO. Oral magnesium chloride: A novel approach in the management of Hailey-Hailey disease. Indian J Dermatol Venereol Leprol 2017; 83:259.</a></li><li><a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/69\" class=\"nounderline abstract_t\">Borghi A, Rimessi A, Minghetti S, et al. Efficacy of magnesium chloride in the treatment of Hailey-Hailey disease: from serendipity to evidence of its effect on intracellular Ca(2+) homeostasis. Int J Dermatol 2015; 54:543.</a></li><li><a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/70\" class=\"nounderline abstract_t\">Albers LN, Arbiser JL, Feldman RJ. Treatment of Hailey-Hailey Disease With Low-Dose Naltrexone. JAMA Dermatol 2017; 153:1018.</a></li><li><a href=\"https://www.uptodate.com/contents/hailey-hailey-disease-benign-familial-pemphigus/abstract/71\" class=\"nounderline abstract_t\">Ibrahim O, Hogan SR, Vij A, Fernandez AP. Low-Dose Naltrexone Treatment of Familial Benign Pemphigus (Hailey-Hailey Disease). JAMA Dermatol 2017; 153:1015.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 15463 Version 15.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H26478811\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H26478746\" id=\"outline-link-H26478746\">INTRODUCTION</a></li><li><a href=\"#H26478753\" id=\"outline-link-H26478753\">EPIDEMIOLOGY</a></li><li><a href=\"#H26478760\" id=\"outline-link-H26478760\">PATHOGENESIS</a></li><li><a href=\"#H26478767\" id=\"outline-link-H26478767\">CLINICAL PRESENTATION AND COURSE</a><ul><li><a href=\"#H20008536\" id=\"outline-link-H20008536\">Clinical course</a></li><li><a href=\"#H23965479\" id=\"outline-link-H23965479\">Risk of squamous cell carcinoma</a></li></ul></li><li><a href=\"#H20009078\" id=\"outline-link-H20009078\">HISTOPATHOLOGY</a></li><li><a href=\"#H26478774\" id=\"outline-link-H26478774\">DIAGNOSIS</a><ul><li><a href=\"#H2060503153\" id=\"outline-link-H2060503153\">Molecular diagnosis</a></li></ul></li><li><a href=\"#H26478790\" id=\"outline-link-H26478790\">DIFFERENTIAL DIAGNOSIS</a></li><li><a href=\"#H1578623156\" id=\"outline-link-H1578623156\">APPROACH TO MANAGEMENT</a><ul><li><a href=\"#H3023347860\" id=\"outline-link-H3023347860\">General measures</a></li><li><a href=\"#H3072059043\" id=\"outline-link-H3072059043\">First-line therapies</a></li><li><a href=\"#H2203744409\" id=\"outline-link-H2203744409\">Second-line therapies</a></li></ul></li><li><a href=\"#H3577992220\" id=\"outline-link-H3577992220\">THERAPEUTIC OPTIONS</a><ul><li><a href=\"#H9327898\" id=\"outline-link-H9327898\">Topical and intralesional therapies</a></li><li><a href=\"#H9327940\" id=\"outline-link-H9327940\">Systemic therapies</a></li><li><a href=\"#H2625410684\" id=\"outline-link-H2625410684\">Surgical or destructive therapies</a></li><li><a href=\"#H2967527976\" id=\"outline-link-H2967527976\">Emerging medical therapies</a></li></ul></li><li><a href=\"#H1785844435\" id=\"outline-link-H1785844435\">GENETIC COUNSELING</a></li><li><a href=\"#H9328049\" id=\"outline-link-H9328049\">PROGNOSIS</a></li><li><a href=\"#H26478811\" id=\"outline-link-H26478811\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DERM/15463|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=DERM/76004\" class=\"graphic graphic_picture\">- Hailey-Hailey 3</a></li><li><a href=\"image.htm?imageKey=DERM/61689\" class=\"graphic graphic_picture\">- Hailey-Hailey 1</a></li><li><a href=\"image.htm?imageKey=DERM/74552\" class=\"graphic graphic_picture\">- Hailey-Hailey 2</a></li><li><a href=\"image.htm?imageKey=OBGYN/80862\" class=\"graphic graphic_picture\">- Hailey Hailey</a></li><li><a href=\"image.htm?imageKey=DERM/75555\" class=\"graphic graphic_picture\">- Haley-Haley histology</a></li><li><a href=\"image.htm?imageKey=DERM/70000\" class=\"graphic graphic_picture\">- Darier disease - dark skin</a></li><li><a href=\"image.htm?imageKey=DERM/56168\" class=\"graphic graphic_picture\">- Darier disease - light skin</a></li><li><a href=\"image.htm?imageKey=DERM/81865\" class=\"graphic graphic_picture\">- Darier disease - nails</a></li><li><a href=\"image.htm?imageKey=DERM/60187\" class=\"graphic graphic_picture\">- Pemphigus vegetans</a></li><li><a href=\"image.htm?imageKey=DERM/53407\" class=\"graphic graphic_picture\">- Seborrheic dermatitis axilla</a></li><li><a href=\"image.htm?imageKey=DERM/68137\" class=\"graphic graphic_picture\">- Seborrheic dermatitis groin</a></li><li><a href=\"image.htm?imageKey=DERM/54173\" class=\"graphic graphic_picture\">- Seborrheic dermatitis scalp</a></li><li><a href=\"image.htm?imageKey=DERM/76985\" class=\"graphic graphic_picture\">- Seborrheic dermatitis scalp 2</a></li><li><a href=\"image.htm?imageKey=DERM/59104\" class=\"graphic graphic_picture\">- Seborrheic dermatitis face 2</a></li><li><a href=\"image.htm?imageKey=PC/79274\" class=\"graphic graphic_picture\">- Inverse psoriasis</a></li><li><a href=\"image.htm?imageKey=DERM/78531\" class=\"graphic graphic_picture\">- Inverse psoriasis chest</a></li><li><a href=\"image.htm?imageKey=DERM/76200\" class=\"graphic graphic_picture\">- Inverse psoriasis groin</a></li><li><a href=\"image.htm?imageKey=DERM/50615\" class=\"graphic graphic_picture\">- Inverse psoriasis gluteal 1</a></li><li><a href=\"image.htm?imageKey=OBGYN/56110\" class=\"graphic graphic_picture\">- Vulvar psoriasis</a></li><li><a href=\"image.htm?imageKey=DERM/70962\" class=\"graphic graphic_picture\">- Nail psoriasis pits</a></li><li><a href=\"image.htm?imageKey=DERM/73527\" class=\"graphic graphic_picture\">- Nail pitting in alopecia areata</a></li><li><a href=\"image.htm?imageKey=DERM/72073\" class=\"graphic graphic_picture\">- Candidal intertrigo groin</a></li><li><a href=\"image.htm?imageKey=PC/78179\" class=\"graphic graphic_picture\">- Severe axillary intertrigo</a></li><li><a href=\"image.htm?imageKey=DERM/71067\" class=\"graphic graphic_picture\">- Tinea cruris 3</a></li><li><a href=\"image.htm?imageKey=DERM/80242\" class=\"graphic graphic_picture\">- Erythrasma in axilla</a></li><li><a href=\"image.htm?imageKey=DERM/59529\" class=\"graphic graphic_picture\">- Erythrasma in axilla 2</a></li><li><a href=\"image.htm?imageKey=DERM/51713\" class=\"graphic graphic_picture\">- Intertriginous erythrasma</a></li><li><a href=\"image.htm?imageKey=DERM/62143\" class=\"graphic graphic_picture\">- Erythrasma fluorescence</a></li></ul></li><li><div id=\"DERM/15463|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DERM/62402\" class=\"graphic graphic_table\">- Topical corticosteroids</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=candidal-intertrigo\" class=\"medical medical_review\">Candidal intertrigo</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=darier-disease\" class=\"medical medical_review\">Darier disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=dermatophyte-tinea-infections\" class=\"medical medical_review\">Dermatophyte (tinea) infections</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-clinical-manifestations-and-diagnosis-of-psoriasis\" class=\"medical medical_review\">Epidemiology, clinical manifestations, and diagnosis of psoriasis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=erythrasma\" class=\"medical medical_review\">Erythrasma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pathogenesis-clinical-manifestations-and-diagnosis-of-pemphigus\" class=\"medical medical_review\">Pathogenesis, clinical manifestations, and diagnosis of pemphigus</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=primary-focal-hyperhidrosis\" class=\"medical medical_review\">Primary focal hyperhidrosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=seborrheic-dermatitis-in-adolescents-and-adults\" class=\"medical medical_review\">Seborrheic dermatitis in adolescents and adults</a></li></ul></div></div>","javascript":null}